Financial Performance - The Group's revenue for the three months ended March 31, 2021, was approximately HK$41.0 million, representing an increase of approximately HK$40.2 million, or 50.25 times, compared to HK$0.8 million for the same period last year[4] - Gross profit for the period was approximately HK$10.6 million, an increase of approximately 14.1 times compared to HK$0.7 million in the prior period, with a gross profit margin decreasing from 91.7% to 26.0%[4] - Profit before income tax from continuing operations was HK$4.9 million, compared to a loss of HK$10.1 million in the prior period[5] - The Group recorded a profit of HK$3.7 million for the period from continuing operations, a significant improvement from a loss of HK$10.1 million in the previous year[5] - The overall loss for the period was HK$7.5 million, an improvement from a loss of HK$13.8 million in the previous year[5] - The loss for the period attributable to owners of the Company was HK$7,656,000, compared to a loss of HK$15,066,000 in the same period last year, representing a 49.1% improvement[7] - Total comprehensive income for the period was HK$3,744,000, a significant recovery from a total comprehensive loss of HK$12,949,000 in the previous year[7] - Profit per share from continuing operations attributable to equity holders was HK$0.129, compared to a loss of HK$1.095 per share in the same period last year[9] - The Company reported a total comprehensive income attributable to owners of HK$3,588,000, compared to a loss of HK$14,723,000 in the previous year[9] Expenses and Cost Management - Cost of sales increased by approximately 458 times from HK$66,000 to approximately HK$30.3 million, aligning with the revenue increase in the healthcare products and services segment[4] - Other income for the period was approximately HK$3.1 million, mainly from COVID-19 related rent concessions[4] - Selling and distribution expenses increased from approximately HK$0.1 million to approximately HK$0.6 million due to efforts to boost revenue[4] - Administrative and other expenses decreased by approximately 20.2%, from HK$9.9 million to approximately HK$7.9 million, due to cost reduction efforts[4] Operational Efficiency - The loss for the period from discontinued operations was HK$11.2 million, compared to a loss of HK$3.6 million in the prior period[5] - The Company experienced a significant reduction in losses from discontinued operations, indicating improved operational efficiency[7] - The financial results reflect a positive trend in the Company's recovery and operational performance compared to the previous year[7] - The Company continues to focus on enhancing its operational strategies to drive future growth and profitability[7] Compliance and Reporting - The unaudited condensed consolidated financial statements for the three months ended March 31, 2021, have been prepared in accordance with Hong Kong Financial Reporting Standards[199] - The financial statements comply with applicable disclosure requirements of the GEM Listing Rules and the Hong Kong Companies Ordinance[199] - The Company is an investment holding company, with its subsidiaries primarily providing healthcare products and services[199] - The Company is listed on the GEM of The Stock Exchange of Hong Kong Limited[199] - The principal activities of the Company's subsidiaries focus on the provision of healthcare products and services[199] - The Company was incorporated in the Cayman Islands on April 20, 2001[199] - The registered office of the Company is located at Cricket Square, Hutchins Drive, P.O. Box 2681, Grand Cayman, KY1-1111, Cayman Islands[199] Reserves and Adjustments - The balance as of January 1, 2020, was restated based on the audited annual results announcement for the year ended December 31, 2019[195] - The special reserve represents the difference between the nominal value of the shares of the acquired subsidiaries and the nominal value of the Company's shares issued for their acquisition[197] - The other reserve includes the difference between the fair value of consideration paid to increase shareholding in subsidiaries and the adjustment to non-controlling interest[197] Other Comprehensive Income - Other comprehensive income for the period included an exchange gain of HK$11,244,000, compared to HK$825,000 in the previous year[7] - Total comprehensive income attributable to owners of the Company from continuing operations was HK$2,272,000, while from discontinued operations it was HK$1,316,000[9]
中国再生医学(08158) - 2021 Q1 - 季度财报